Pharvaris (NASDAQ:PHVS) Given New $30.00 Price Target at Bank of America
Bank of America increased their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the company a "neutral" rating in a research note on Thursday...
MarketBeat·6d ago
More News
Pharvaris (NASDAQ:PHVS) Given New $30.00 Price Target at Bank of America
Bank of America increased their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the company a "neutral" rating in a research note on Thursday...
MarketBeat·6d ago
Pharvaris (NASDAQ:PHVS) Given "Buy" Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Pharvaris in a research report on Wednesday...
MarketBeat·7d ago
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·7d ago
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·7d ago
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·7d ago
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Zacks·7d ago
Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Should You Buy?
Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Here's What Happened...
MarketBeat·7d ago
PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment
The RAPIDe-3 Phase 3 study is Pharvaris’ first trial for on-demand treatment of HAE attacks.
Stocktwits·8d ago
Pharvaris (NASDAQ:PHVS) Sets New 1-Year High - What's Next?
Pharvaris (NASDAQ:PHVS) Sets New 52-Week High - Here's Why...